⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16821953 | 0.83 | SIGMAR1 (0.31) | — | |
| SCHEMBL4392294 | 0.80 | — | — | |
| SCHEMBL9831334 | 0.80 | SIGMAR1 (0.31) | — | |
| SCHEMBL9614563 | 0.74 | — | — | |
| SCHEMBL29111392 | 0.72 | TP53 (0.31) | — | |
| SCHEMBL5933319 | 0.70 | — | — | |
| SCHEMBL27802396 | 0.70 | — | — | |
| SCHEMBL186948 | 0.69 | — | — | |
| SCHEMBL1665817 | 0.69 | — | — | |
| SCHEMBL7064226 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1664027-A1 | SUBSTITUTED 2,3-DIHYDRO-1H-ISOINDOL-1-ONE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2006-06-07 | — | — | EP | disclosed |
| EP-1442140-A4 | ANTISENSE MODULATION OF INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 5 EXPRESSION | ISIS PHARMACEUTICALS INC (US) | 2005-08-10 | — | — | EP | disclosed |
| EP-1537084-A1 | SUBSTITUTED 2-ALKYLAMINE NICOTINIC AMIDE DERIVATIVES AND USE THERE OF | Amgen Inc. (US) | 2005-06-08 | — | — | EP | disclosed |
| WO-2005021532-A1 | SUBSTITUTED 2,3-DIHYDRO-1H-ISOINDOL-1-ONE DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2005-03-10 | — | — | WO | disclosed |
| EP-1461461-A2 | ANTISENSE MODULATION OF CD81 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2004-09-29 | — | — | EP | disclosed |
| EP-1461352-A2 | ANTISENSE MODULATION OF CONNECTIVE TISSUE GROWTH FACTOR EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2004-09-29 | — | — | EP | disclosed |
| EP-1461463-A2 | ANTISENSE MODULATION OF HEMATOPOIETIC CELL PROTEIN TYROSINE KINASE EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2004-09-29 | — | — | EP | disclosed |
| EP-1442140-A2 | ANTISENSE MODULATION OF INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 5 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2004-08-04 | — | — | EP | disclosed |
| EP-1417216-A2 | ANTISENSE MODULATION OF BCL2-ASSOCIATED X PROTEIN EXPRESSION | ISIS Pharmaceuticals, Inc. (US) | 2004-05-12 | — | — | EP | disclosed |
| EP-1392867-A2 | ANTISENSE MODULATION OF PTP1B EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2004-03-03 | — | — | EP | disclosed |
| WO-2003011888-A1 | ANTISENSE MODULATION OF SAP-1 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2003-02-13 | — | — | WO | disclosed |
| WO-2003008543-A2 | ANTISENSE MODULATION OF BCL2-ASSOCIATED X PROTEIN EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2003-01-30 | — | — | WO | disclosed |
| WO-2002092855-A1 | ANTISENSE MODULATION OF HELICASE-MOI EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2002-11-21 | — | — | WO | disclosed |
| WO-2002092772-A2 | ANTISENSE MODULATION OF PTP1B EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2002-11-21 | — | — | WO | disclosed |
| WO-2002088393-A1 | ANTISENSE MODULATION OF TUMOR NECROSIS FACTOR RECEPTOR 2 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2002-11-07 | — | — | WO | disclosed |
| WO-2002070536-A1 | ANTISENSE MODULATION OF RECQL2 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2002-09-12 | — | — | WO | disclosed |
| WO-2002068672-A2 | ANTISENSE MODULATION OF RECQL4 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2002-09-06 | — | — | WO | disclosed |
| WO-2002020550-A1 | ANTISENSE MODULATION OF MEKK3 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2002-03-14 | — | — | WO | disclosed |
| WO-2002010185-A1 | ANTISENSE MODULATION OF LYSOPHOSPHOLIPASE I EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2002-02-07 | — | — | WO | disclosed |
| WO-2001000651-A1 | ANTISENSE MODULATION OF G-ALPHA-i3 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2001-01-04 | — | — | WO | disclosed |